FibroGen, Inc (FGEN) Receives Average Rating of “Buy” from Brokerages
FibroGen, Inc (NASDAQ:FGEN) has earned an average recommendation of “Buy” from the nine research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $66.60.
FGEN has been the subject of a number of recent analyst reports. Stifel Nicolaus reiterated a “buy” rating and issued a $80.00 price target on shares of FibroGen in a research report on Thursday, September 14th. Jefferies Group LLC restated a “buy” rating and set a $75.00 target price on shares of FibroGen in a research note on Tuesday, September 12th. William Blair reaffirmed an “outperform” rating on shares of FibroGen in a report on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) lowered FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price target for the company. in a research note on Friday, July 21st. Finally, BidaskClub cut FibroGen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st.
In related news, CEO Thomas B. Neff sold 38,636 shares of the company’s stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $53.46, for a total transaction of $2,065,480.56. Following the sale, the chief executive officer now owns 3,246,754 shares of the company’s stock, valued at $173,571,468.84. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Pat Cotroneo sold 95,000 shares of the company’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $50.61, for a total transaction of $4,807,950.00. Following the sale, the vice president now directly owns 173,366 shares in the company, valued at approximately $8,774,053.26. The disclosure for this sale can be found here. In the last ninety days, insiders sold 506,828 shares of company stock worth $22,574,671. Corporate insiders own 14.90% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. purchased a new position in shares of FibroGen in the 1st quarter worth $111,000. Quantbot Technologies LP bought a new stake in shares of FibroGen in the 2nd quarter worth about $128,000. SG Americas Securities LLC increased its holdings in shares of FibroGen by 6.5% in the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 412 shares during the last quarter. Amalgamated Bank bought a new stake in shares of FibroGen in the 2nd quarter worth about $237,000. Finally, BNP Paribas Arbitrage SA increased its holdings in shares of FibroGen by 589.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,401 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 6,327 shares during the last quarter. Institutional investors and hedge funds own 47.49% of the company’s stock.
FibroGen (NASDAQ FGEN) opened at 56.05 on Wednesday. The company’s 50-day moving average is $48.38 and its 200 day moving average is $34.57. FibroGen has a 52 week low of $15.60 and a 52 week high of $56.15. The stock’s market cap is $3.99 billion.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.01). The company had revenue of $29.00 million for the quarter, compared to analysts’ expectations of $34.80 million. FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. On average, analysts expect that FibroGen will post ($1.80) earnings per share for the current fiscal year.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.